# Ph 2 Study of the Safety and Efficacy of Three HU6 Dose Levels and Placebo in Nonalcoholic Steatohepatitis

> **NCT05979779** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Rivus Pharmaceuticals, Inc.** · enrollment: 219 (actual)

## Conditions studied

- Non-Alcoholic Fatty Liver Disease
- Nonalcoholic Steatohepatitis
- Fatty Liver

## Interventions

- **DRUG:** HU6
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT05979779
- **Lead sponsor:** Rivus Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-09-05
- **Primary completion:** 2025-01-21
- **Final completion:** 2025-06
- **Target enrollment:** 219 (ACTUAL)
- **Last updated:** 2025-04-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05979779

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05979779, "Ph 2 Study of the Safety and Efficacy of Three HU6 Dose Levels and Placebo in Nonalcoholic Steatohepatitis". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT05979779. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*